Literature DB >> 31904564

Syndromic panels or 'panel syndrome'? A perspective through the lens of respiratory tract infections.

M-C Zanella1, P Meylan2, L Kaiser3.   

Abstract

Entities:  

Keywords:  Diagnosis; Influenza; Multiplex; Panel; Pneumonia; Respiratory syncytial virus; Respiratory tract infection; Viral disease; Virus

Mesh：

Year:  2020        PMID： 31904564     DOI： 10.1016/j.cmi.2019.12.018

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  5 in total

1.  The DendrisCHIP® Technology as a New, Rapid and Reliable Molecular Method for the Diagnosis of Osteoarticular Infections.

Authors:  Elodie Bernard; Thomas Peyret; Mathilde Plinet; Yohan Contie; Thomas Cazaudarré; Yannick Rouquet; Matthieu Bernier; Stéphanie Pesant; Richard Fabre; Aurore Anton; Cathy Maugis-Rabusseau; Jean Marie François
Journal:  Diagnostics (Basel)       Date:  2022-05-30

Review 2.  Acute Viral Gastrointestinal (GI) Infections in the Tropics-A Role for Cartridge-Based Multiplex PCR Panels?

Authors:  Stefanie Kramme; Theo Dähne; Alexey Fomenko; Marcus Panning
Journal:  Trop Med Infect Dis       Date:  2022-05-19

3.  Rapid syndromic testing for respiratory viral infections in children attending the emergency department during COVID-19 pandemic in Lille, France, 2021-2022.

Authors:  Mahdi Ouafi; François Dubos; Ilka Engelman; Mouna Lazrek; Aurélie Guigon; Laurence Bocket; Didier Hober; Enagnon Kazali Alidjinou
Journal:  J Clin Virol       Date:  2022-06-25       Impact factor: 14.481

Review 4.  Value of syndromic panels in the management of severe community-acquired pneumonia.

Authors:  A Burillo; F J Candel; A Canut-Blasco
Journal:  Rev Esp Quimioter       Date:  2022-04-22       Impact factor: 2.515

5.  Syndromic panels or the panels' syndrome? A perspective through the lens of respiratory tract infections: author's response.

Authors:  M-C Zanella; P Meylan; L Kaiser
Journal:  Clin Microbiol Infect       Date:  2020-03-28       Impact factor: 8.067
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.